Inmune Bio Inc stock (US45764T1060): Alzheimer’s MRI data lift focus on Phase 2 MINDFuL trial

Nasdaq-traded Inmune Bio is drawing renewed attention from U.S. biotech investors this week after the company reported statistically significant changes in an advanced white matter MRI biomarker from its Phase 2 MINDFuL trial in Alzheimer’s disease, sharpening the focus on its lead program while the stock still trades in the low single digits.

On 06/02/2026, the Boca Raton, Florida-based company announced that patients treated with its TNF-targeting drug candidate XPro1595 showed a statistically significant treatment effect on a myelin-based MRI biomarker compared with placebo after 24 weeks of therapy in the MINDFuL study, according to a company press release published via GlobeNewswire on that date and accessible through the investor relations section of Inmune Bio’s website.

The company reported that in the full modified intention-to-treat population of approximately 200 patients, the analysis showed a p-value of 0.0028 and a Cohen’s d effect size of 0.46 on the advanced white matter biomarker, which was interpreted as a medium effect size over the 24-week treatment period, according to the same 06/02/2026 release.

In a biomarker-enriched subset of around 100 patients selected for higher inflammatory or imaging risk profiles, Inmune Bio highlighted a p-value of 0.0098 with a Cohen’s d of 0.59, suggesting what the company characterized as a larger treatment effect in this group, based on the independently conducted MRI analysis summarized in the 06/02/2026 communication.

The MRI assessment was conducted in a blinded manner by an external imaging core lab, which, according to the company’s description in the 06/02/2026 release, was responsible for quantifying changes in white matter myelin integrity and provided the statistical output that underpins the reported p-values and effect sizes in both the overall and biomarker-enriched populations.

U.S. equity investors have been quick to note that the readout focuses on an imaging biomarker rather than traditional cognitive endpoints at this stage, but the data still provide one of the clearer objective measures of XPro1595’s biological activity in Alzheimer’s disease to date, as underlined by coverage on financial news platforms that summarized the results on 06/02/2026 and 06/03/2026, citing the same company figures.

As of the latest trading session referenced in those reports, Inmune Bio’s shares changed hands at around USD 1.39 on the Nasdaq Capital Market under the ticker INMB, implying a market capitalization in the mid-thirty-million-dollar range, a level that underscores both the early-stage risk profile and the potential for volatility often seen in U.S.-listed clinical-stage biotech stocks at this price range.

The U.S. listing means the company’s primary investor base is anchored in the United States, with trading and liquidity centered on the Nasdaq venue; at the same time, some European retail investors can access the stock via German trading platforms such as Tradegate, where parallel quotations typically mirror the U.S. price in euro terms, although volumes are markedly lower than on the home exchange.

In the press materials dated 06/02/2026, Inmune Bio stated that the MRI results will help inform further development plans for XPro1595 in Alzheimer’s disease, including discussions with regulatory agencies on how advanced imaging biomarkers such as myelin-sensitive MRI could be integrated into future trial designs alongside clinical endpoints.

The company also emphasized in the same communication that the MINDFuL trial remains focused on patients with mild Alzheimer’s disease and that the reported results relate to a 24-week treatment window, meaning that longer-term outcomes and cognitive data will still be key components of any subsequent regulatory filing strategy in the United States or other markets.

For U.S. investors tracking small-cap biotech names, the combination of a statistically significant imaging readout, a modest market capitalization and listing on the Nasdaq Capital Market is likely to keep Inmune Bio on watch lists, especially as the Alzheimer’s treatment landscape has been evolving rapidly with new antibody therapies and a growing focus on disease-modifying mechanisms.

Beyond the immediate trial update, the company’s communication on 06/02/2026 reiterated that it remains a late-stage biotechnology player concentrating on inflammation and immunology pathways, with XPro1595 positioned as a potential disease-modifying therapy that targets soluble TNF in neurodegenerative conditions such as Alzheimer’s disease rather than simply addressing symptomatic relief.

Against this backdrop, the recent MRI findings give U.S. market participants one of the clearest data points yet on tissue-level effects of XPro1595 in the brain’s white matter, even as investors await more traditional clinical outcome measures that will ultimately be required to shape any future FDA approval pathway.

As of: 06/03/2026

By the editorial team - specialized in equity coverage.

Inmune Bio Inc: core business model

Inmune Bio positions itself as a late-stage U.S. biotech group that designs therapies aimed at modulating the innate immune system, with prospective revenues expected to depend heavily on the successful clinical and regulatory progression of its lead asset XPro1595 and a small pipeline of inflammation-focused candidates.

Inmune Bio Inc in peer comparison

Given its focus on Alzheimer’s disease and innate immune modulation, Inmune Bio is often compared with other U.S.-listed biotech developers targeting neurodegeneration, such as companies working on monoclonal antibodies or alternative mechanisms that seek to alter the course of Alzheimer’s rather than only treating symptoms.

While larger peers pursuing Alzheimer’s therapies may already have approved products or late-stage Phase 3 programs and therefore command substantially higher market capitalizations, Inmune Bio’s profile as a Nasdaq small cap with statistically significant MRI biomarker data but without yet having late-stage confirmatory cognitive data places it in a higher-risk segment of the U.S. biotech space relative to more diversified or revenue-generating rivals.

Conclusion

The newly reported MRI biomarker findings from the Phase 2 MINDFuL trial give Inmune Bio a data-backed narrative around tissue-level effects of XPro1595 in Alzheimer’s disease, at a time when its Nasdaq-listed shares still trade at what is typically considered a micro-cap valuation for a U.S. biotech stock.

In the context of its peer group, the company remains materially smaller and earlier-stage than many Alzheimer’s-focused competitors, which keeps risk levels high but also means that further clinical readouts or regulatory interactions tied to imaging and cognitive endpoints will likely be key catalysts for how U.S. and international investors assess the stock’s position within the broader neurodegeneration space.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.